期刊
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
卷 39, 期 3, 页码 264-272出版社
SPRINGER
DOI: 10.1007/s11239-015-1194-6
关键词
Anticoagulants; Dabigatran; Rivaroxaban; Apixaban; Antidotes; Non-vitamin K oral anticoagulants
Oral anticoagulants are a mainstay for the prevention and treatment of venous and arterial thrombosis. In 2015, the non-vitamin K oral anticoagulants (NOACs) are already replacing warfarin for many indications. Ongoing studies are focused on development of antidotes and specific reversal agents for the NOACs, and assessing their utility for prevention of cardiovascular events in patients with heart failure, coronary or peripheral artery disease, or embolic stroke of unknown source. This paper (a) lists the current indications for the NOACs; (b) reviews the current impact of the NOACs in each of these indications; (c) outlines future opportunities for the NOACs, and (e) provides perspective on new anticoagulant strategies that may be safer than the NOACs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据